You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》高盛首予德琪醫藥-B(06996.HK)「買入」評級 目標價23.61元
阿思達克 12-23 11:11
高盛發表研究報告,相信德琪醫藥-B(06996.HK)具有強大的研發及商業能力,有潛力成為亞太區腫瘤治療領域的領先企業之一。首次給予「買入」投資評級,目標價23.61元。

該行指,公司有12種候選藥物覆蓋新型致癌途徑,預期其主要資產selinexor的銷售將會在2021年底在中國以外的亞太地區開始,中國的銷售則在2022年展開,料及至2030年中國的經調整風險銷售額為32億元人民幣。除了selinexor,2021及2022年的其他里程碑還包括ATG-008(mTORC1/2)及ATG-016(XPO1)的早期試驗啟動,以及為另外三項資產進行IND申請。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account